David S Fedson
- Commentary: From scarcity to abundance: pandemic vaccines and other agents for "have not" countriesDavid S Fedson
University College London, UK
J Public Health Policy 28:322-40. 2007..The "have not" countries must continue to put pressure on WHO and leading countries to ensure that they will have access to the interventions they will need...
- How to optimise the coverage rate of infant and adult immunisations in EuropeHeinz J Schmitt
Infectious Diseases Service at the Zentrum für Präventive Pädiatrie, Johannes Gutenberg Universitat, Mainz, Germany
BMC Med 5:11. 2007..Although vaccination has been proved to be a safe, efficacious, and cost-effective intervention, immunisation rates remain suboptimal in many European countries, resulting in poor control of many vaccine-preventable diseases...
- Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidenceDavid S Fedson
Lancet Infect Dis 3:272-3; discussion 273-4. 2003
- Pandemic influenza: a potential role for statins in treatment and prophylaxisDavid S Fedson
Clin Infect Dis 43:199-205. 2006..Generic statins will be widely distributed and inexpensive. They might be the only agents that could alter the course of a global pandemic...
- Vaccine development for an imminent pandemic: why we should worry, what we must doDavid S Fedson
Hum Vaccin 2:38-42. 2006..Vaccination for an imminent pandemic requires a global perspective not only for vaccine development but also for vaccine production and distribution...
- Confronting an influenza pandemic with inexpensive generic agents: can it be done?David S Fedson
Lancet Infect Dis 8:571-6. 2008....
- NEW technologies for meeting the global demand for pandemic influenza vaccinesDavid S Fedson
Biologicals 36:346-9. 2008..These technologies could help meet the global demand for pandemic vaccines, but only if they are coupled with improvements in the human infrastructure necessary for pandemic vaccination...
- Meeting the challenge of influenza pandemic preparedness in developing countriesDavid S Fedson
Emerg Infect Dis 15:365-71. 2009..Without this research, industrialized and developing countries could face an unprecedented health crisis...
- Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might workDavid S Fedson
Influenza Other Respi Viruses 3:129-42. 2009..Research is urgently needed to determine whether these and other agents that modify the host response might be useful in managing H5N1 influenza and the next pandemic...
- Preparing for pandemic vaccination: an international policy agenda for vaccine developmentDavid S Fedson
J Public Health Policy 26:4-29. 2005..Whether this international policy agenda for pandemic vaccine development will succeed is uncertain, but it will provide a good indication of whether "good governance" for global public health can be achieved...
- Pneumococcal polysaccharide vaccination for adults: new perspectives for EuropeDavid S Fedson
57 Chemin du Lavoir, 01630 Sergy Haut, France
Expert Rev Vaccines 10:1143-67. 2011....
- Pandemic influenza and the global vaccine supplyDavid S Fedson
Clin Infect Dis 36:1552-61. 2003....
- Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adultsDavid S Fedson
Aventis Pasteur MSD, Lyon, France
Vaccine 22:927-46. 2004..This evidence is sufficient to justify wider use of pneumococcal vaccine...
- Vaccination for pandemic influenza and severe acute respiratory syndrome: common issues and concernsDavid S Fedson
Clin Infect Dis 36:1562-3. 2003
- Pneumococcal vaccination in older adultsDavid S Fedson
N Engl J Med 349:712-4; author reply 712-4. 2003
- Vaccination for pandemic influenza: a six point agenda for interpandemic yearsDavid S Fedson
, Sergy Haut, France
Pediatr Infect Dis J 23:S74-7. 2004..This will require the skills not only of experts in virology, epidemiology and public health but also those in politics, economics and law. The task will be complex, but its promised benefits will be immense...
- Influenza vaccination: policy versus evidence: no gap between policy and evidenceDavid S Fedson
BMJ 333:1020. 2006
- Interview with David S. Fedson, MD, Former Professor of Medicine, University of Virginia School of Medicine, and Director of Medical Affairs, Aventis Pasteur MSD by Madeline DrexlerDavid S Fedson
Biosecur Bioterror 3:9-15. 2005
- Statins and the risk of pneumonia: a population-based, nested case-control studyRaymond G Schlienger
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
Pharmacotherapy 27:325-32. 2007..To determine if the use of statins affects pneumonia-related outpatient visits, hospitalizations with survival, and deaths...
- Statin protection against influenza and COPD mortalityDavid S Fedson
Chest 132:1406; author reply 1406-7. 2007
- The conjugate vaccine and invasive pneumococcal diseaseDavid S Fedson
N Engl J Med 349:714-6; author reply 714-6. 2003
- Influenza and the winter increase in mortality in the United States, 1959-1999Thomas A Reichert
Entropy Research Institute, 262 West Saddle River Road, Upper Saddle River, NJ 07458, USA
Am J Epidemiol 160:492-502. 2004..Weather and other factors may determine the timing and modulate the magnitude of the winter-season increase in mortality, but the primary determinant appears to be the influenza virus...
- Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control studyAngela Dominguez
Department of Health, Generalitat of Catalonia, Barcelona, Spain
Clin Infect Dis 40:1250-7. 2005..We evaluated the effectiveness of a 23-valent pneumococcal vaccination program for elderly people in Catalonia, Spain, in a matched-set case-control study...